Professional Overview

Sharon Yavrom is a seasoned executive in the clinical science industry, currently serving as the Executive Director of Clinical Science at Imugene Limited in San Diego, CA. Her expertise spans clinical development, medical affairs, and research, with a strong focus on oncology and pharmaceuticals.

Experience Summary

Current Role

As the Executive Director of Clinical Science at Imugene Limited, Sharon is responsible for leading clinical development strategies, overseeing clinical trials, and collaborating with cross-functional teams to drive business growth. Her key accomplishments include driving clinical development programs forward and contributing to the company's growth in the oncology space.

Career Progression

Sharon's career progression is marked by notable roles at Oncternal Therapeutics, Mei Pharma, Aduro Biotech, Tocagen Inc., Puma Biotechnology, Inc., Synta Pharmaceuticals, and Amgen. Her career trajectory demonstrates consistent growth, with increasing responsibilities and achievements in clinical science, medical affairs, and research.

Academic Background

Sharon holds a Ph.D. in Pathobiology from the University of Southern California and a Bachelor's degree in Biology from San Jose State University. Her academic background provides a strong foundation in biology, pathology, and research.

Areas of Expertise

Sharon's areas of expertise include clinical development, medical affairs, research, oncology, pharmaceuticals, leadership, and management. She possesses strong technical competencies, including clinical trial management, data analysis, and regulatory affairs.

Professional Impact

Sharon has made significant contributions to the industry through her work on various clinical development programs, medical affairs initiatives, and research projects. Her measurable achievements include driving business growth, improving clinical trial efficiency, and enhancing patient outcomes.

Conclusion

Sharon Yavrom is a highly accomplished executive in the clinical science industry, with a strong track record of driving business growth, leading cross-functional teams, and contributing to the development of innovative therapies. Her current focus is on leading clinical development strategies at Imugene Limited, and her value proposition lies in her expertise, leadership, and commitment to delivering high-quality results in the oncology space.